Ditchcarbon
  • Contact
  1. Organizations
  2. Bioverativ Therapeutics Inc.
Public Profile
Research Pending

This profile hasn't yet passed our validation checks

Submit your email to push it up the queue

We'll prioritize this organization's research and notify you when detailed sustainability data becomes available.

Pharmaceutical Preparation Manufacturing
US
updated 7 months ago

Bioverativ Therapeutics Inc.

Company website

Bioverativ Therapeutics Inc., a leading biotechnology company headquartered in the United States, focuses on developing innovative therapies for patients with rare blood disorders. Founded in 2017, Bioverativ has quickly established itself in the biopharmaceutical industry, particularly in the areas of haemophilia and other blood-related conditions. The company’s core products, including its advanced therapies for haemophilia A and B, are distinguished by their unique mechanisms of action and commitment to improving patient outcomes. Bioverativ's dedication to research and development has positioned it as a key player in the market, achieving significant milestones in clinical trials and product launches. With a strong emphasis on patient-centric solutions, Bioverativ continues to make strides in transforming the treatment landscape for individuals with bleeding disorders.

DitchCarbon Score

How does Bioverativ Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

100

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

32

Industry Benchmark

Bioverativ Therapeutics Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

100%

Let us know if this data was useful to you

Bioverativ Therapeutics Inc.'s reported carbon emissions

Inherited from Sanofi

Bioverativ Therapeutics Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Sanofi, which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its climate strategy, Bioverativ follows initiatives set by Sanofi, which include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative. These initiatives aim to promote transparency and accountability in carbon emissions reduction and sustainability efforts. While specific reduction targets or achievements for Bioverativ are not detailed, the alignment with Sanofi's broader climate commitments suggests a focus on reducing emissions across all scopes. The absence of direct emissions data highlights the need for ongoing efforts in climate action and transparency within the biopharmaceutical sector.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20102011201220132015201920202021202220232024
Scope 1
545,114,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
677,549,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
-
000,000,000
000,000,000
00,000,000
00,000,000
Scope 3
-
-
-
0,000,000,000
-
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Bioverativ Therapeutics Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Bioverativ Therapeutics Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Bioverativ Therapeutics Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Novo Nordisk Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 25 days ago

Shire US, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 25 days ago

CSL Behring LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated 25 days ago

Nautilus Biotech S.A.

FR
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251009.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy